~ Buy the SALONPAS (menthol; methyl salicylate) Drug Profile, 2024 PDF Report in the Report Store ~

SALONPAS Drug Patent Profile

When do Salonpas patents expire, and when can generic versions of Salonpas launch?

Salonpas is a drug marketed by Hisamitsu Pharm Co and is included in one NDA. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the menthol; methyl salicylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Salonpas

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 3, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SALONPAS

International Patents:	20
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
Patent Applications:	78
DailyMed Link:	SALONPAS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SALONPAS

NDA:

022029

Dosage:

PATCH;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SALONPAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Scilex Pharmaceuticals, Inc.	Phase 1

See all SALONPAS clinical trials

US Patents and Regulatory Information for SALONPAS

SALONPAS is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-001	Feb 20, 2008		OTC	Yes	Yes			Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-002	Nov 5, 2012		OTC	Yes	No			Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-001	Feb 20, 2008		OTC	Yes	Yes			Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-002	Nov 5, 2012		OTC	Yes	No			Y

International Patents for SALONPAS

When does loss-of-exclusivity occur for SALONPAS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Japan

Malaysia

Mexico

New Zealand

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SALONPAS around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200817013	Adhesive preparation
Malaysia	149142	ADHESIVE PREPARATION
South Korea	101420450
Russian Federation	2441649	АДГЕЗИВНЫЙ ПРЕПАРАТ (ADHESIVE PRODUCT)

SALONPAS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Salonpas

Introduction

Salonpas, a pioneering brand in topical pain relief, has been a cornerstone in the pharmaceutical industry for 90 years. Here, we delve into the market dynamics and financial trajectory of Salonpas, highlighting its growth, innovations, and future prospects.

Historical Growth and Milestones

Since its introduction, Salonpas has experienced remarkable growth, particularly in the U.S. market. From 2010 to 2023, retail sales of Salonpas surged over tenfold, reaching an impressive $200 million[1][4].

Market Performance

• U.S. Market Dominance: Salonpas has become a leader in the U.S. topical pain relief market, with record sales across various retail channels, including food, drug, mass, club, and e-commerce platforms[1][4].
• Consumer Adoption: Despite its success, less than 1 in 3 U.S. households purchase products in the External Analgesics category, with Salonpas attracting only about 1 in 20 households. However, those who have discovered Salonpas are highly satisfied and brand loyal[1][4].

Innovation and Product Development

Salonpas has maintained its market position through continuous innovation:

• New Product Launches: The Salonpas Lidocaine 4% Pain Relieving FLEX Patch was distinguished as the #1 new item in the External Analgesics OTC category, further solidifying the brand's commitment to innovation[1][4].
• Technological Advancements: The brand has benefited from advancements in drug delivery systems, such as microencapsulation and nano-formulations, which enhance the efficacy and convenience of topical pain relief products[3].

Financial Trajectory

• Revenue Growth: Hisamitsu America, the parent company of Salonpas, has seen significant revenue growth driven by the success of Salonpas. In the OTC pharmaceuticals business, sales have increased substantially, contributing to the company's overall financial performance[2][5].
• Profitability: The company has reported double-digit revenue growth and triple-digit operating and net profit growth, primarily driven by the success of Salonpas in the OTC segment[5].
• Global Financials: Hisamitsu Pharmaceutical's consolidated financial statements show a robust financial position, with net sales, operating profit, and net assets increasing over the years. For instance, in FY2019, net sales were ¥143,408 million, and net assets totaled ¥248,161 million[2].

Market Segmentation and Regional Performance

• Global Market: The global topical pain relief market is projected to grow from $10.5 billion in 2023 to $17.1 billion by 2032, with a compound annual growth rate (CAGR) of 5.6%[3].
• Regional Dominance: North America holds a significant share of the market, driven by chronic pain prevalence and robust healthcare infrastructure. The Asia Pacific region is also experiencing rapid growth due to demographic shifts and increased healthcare access[3].

Consumer Preferences and Market Drivers

• Aging Population: The growing global population suffering from arthritis and musculoskeletal disorders is a key driver for the topical pain relief market[3].
• Non-Pharmacological Preferences: Consumers are increasingly preferring non-pharmacological and non-invasive treatment modalities, which has driven the adoption of topical pain relief products like Salonpas[3].

Competitive Landscape

• Brand Loyalty: Salonpas is recognized as the #1 Doctor and Pharmacist recommended OTC Topical Pain Patch Brand, and it has more Facebook fans and followers than any other systemic or topical OTC analgesic brand[1][4].
• Market Leadership: According to Euromonitor International, Salonpas is the world's No. 1 OTC topical analgesic patch brand, underscoring its market leadership[4].

Challenges and Opportunities

• Regulatory Challenges: The market faces stringent regulatory landscapes, particularly for prescription-based treatments. However, opportunities exist in leveraging online distribution channels and enhancing product innovation[3].
• Emerging Markets: There are significant opportunities in tapping into emerging markets with unmet healthcare demands, which could further drive the growth of Salonpas and the broader topical pain relief market[3].

Future Prospects

• Continuous Innovation: Hisamitsu America's commitment to research and development is expected to continue driving innovation in the topical pain relief category, ensuring the brand remains at the forefront of the market[1][3].
• Market Expansion: The goal to bring more people under the "topicals tent," especially in regions like Japan, suggests a strategic focus on expanding market share and consumer adoption[1][4].

Key Takeaways

• Salonpas has achieved remarkable growth in the U.S. market, with retail sales exceeding $200 million in 2023.
• The brand is a leader in innovation, with products like the Salonpas Lidocaine 4% Pain Relieving FLEX Patch.
• The global topical pain relief market is poised for significant growth, driven by an aging population and advancements in drug delivery technologies.
• Salonpas faces challenges in regulatory landscapes but has opportunities in emerging markets and online distribution channels.
• The brand's commitment to research and development ensures its continued market dominance.

FAQs

Q: What is the current market value of Salonpas in the U.S.? A: Salonpas retail sales exceeded $200 million in 2023, with record sales across various retail channels[1][4].

Q: What drives the growth of the topical pain relief market? A: Key drivers include the aging global population, advancements in drug delivery technologies, and consumer preferences for non-pharmacological treatments[3].

Q: Is Salonpas a recommended brand by healthcare professionals? A: Yes, Salonpas is the #1 Doctor and Pharmacist recommended OTC Topical Pain Patch Brand according to IQVIA: ProVoice Survey 2023[4].

Q: What are the future prospects for Salonpas? A: Salonpas is expected to continue innovating and expanding its market share, particularly in regions with unmet healthcare demands[1][3].

Q: How does Salonpas compare to other OTC analgesic brands in terms of consumer engagement? A: Salonpas has more Facebook fans and followers than any other systemic or topical OTC analgesic brand[1][4].

Cited Sources

1. Hisamitsu America Marks 90 Years of Pioneering Pain Relief with Salonpas - Hisamitsu America Blog
2. Annual Report 2019 - Hisamitsu Pharmaceutical
3. Topical Pain Relief Market Report 2024 - GlobeNewswire
4. Hisamitsu America Marks 90 Years of Pioneering Pain Relief with Salonpas - Markets Insider
5. Strong Q3 Result Driven by Salonpas; FY23 Guidance Reiterated - SmartKarma